ATM positive

This Quality Initiative to improve testing and identification of HRR mutations in patients with mCRPC led to a 33% relative increase in HRR testing, demonstrating how QI programs can transform care and move the field toward individualized, precision medicine.

P2, N=229, Completed, Bayer | Recruiting --> Completed | Trial completion date: Apr 2025 --> Sep 2023

P2, N=202, Terminated, Pfizer | Active, not recruiting --> Terminated; The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)

Our results demonstrated the unique clinical and molecular features of pathogenic ATM/ATR mutations in NSCLC, which helps better understand the cancerous involvement of these DDR regulators, as well as directing targeted therapies and/or immunotherapies to treat ATM/ATR-mutated NSCLC patients, especially those with co-existing FA/HR aberrations.

P2, N=239, Recruiting, Bayer | Trial completion date: Apr 2024 --> Apr 2025

The aTMTV algorithm demonstrated good performance for the measurement of TMTV in patients with non-Hodgkin lymphoma, while showing good generalizability across lymphoma subtypes, patient subpopulations and PET/CT scanner manufacturers. Reduced algorithm performance for small lesions (≤ 10 mL) may be the result of higher variability among readers in the determination of small lesions; future work aims to refine and optimize performance of the algorithm for use as a prognostic tool in clinical practice. Artificial intelligence, Lymphoma, Tumor, FDG-PET

He underwent 6 cycles of palliative chemotherapy with carboplatin and Taxol for carcinoma of unknown origin...He received suppressive dose levothyroxine...For rectal cancer, he received radiation therapy and capecitabine.Our case is interesting for several reasons...Combination therapy with Lenvatinib and Pembrolizumab is currently under trial for aggressive thyroid malignancy...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

This quality initiative to improve testing and identification of HRR mutations in patients with mCRPC led to a 33% relative increase in HRR testing. Quality initiative programs are critical to transforming cancer care and moving the field closer toward individualized, precision medicine.

This real-world study shows an opportunity to increase rates of PARPi treatment in patients with HRRm mCRPC across all HRR gene mutations. mCRPC patients with BRCA and ATM mutations were more likely to receive PARPi than those with other HRR mutations.

Notably, while we saw strong familial patterns in MPN families, germline testing did not always detect a hereditary component; 8/9 patients with a first-degree family history of MPN had no actionable variants. While the hereditary nature of MPNs should be considered in clinical analysis, larger cohort studies are needed to determine stronger clinical markers of germline inheritance.

Thus, this study suggests a new angle of ATM mutations in MCL pathogenesis which could improve risk stratification. Overall, this study may unravel distinct mechanisms of tumorigenesis with relevant clinical and biological implications.